timothy sykes logo
Moderna Stock Jumps As Q1 Beat Fuels Vaccine And Oncology Hopes Thumbnail
G Google News

Moderna Stock Jumps As Q1 Beat Fuels Vaccine And Oncology Hopes

ELLIS HOBBS•UPDATED MAY. 9, 2026, 10:06 AM ET
Reviewed by Jack Kelloggand Fact-checked by Tim Sykes

Moderna Inc. stocks have been trading up by 16.03 percent amid highly positive sentiment surrounding its latest vaccine advances.

Candlestick Chart

Weekly Update May 04 – May 08, 2026: On Saturday, May 09, 2026 Moderna Inc. stock [NASDAQ: MRNA] is trending up by 16.03%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Moderna’s current fundamentals are weak but strategically improving as it pivots from pandemic windfall to a diversified vaccine and oncology platform. Q1 2026 revenue of $389M and trailing revenue of ~$1.9B sit against deeply negative EBIT and profit margins, reflecting heavy R&D and one‑off litigation costs. Yet cash and investments of ~$5.2B and low leverage (debt/equity 0.15, current ratio 3.3) provide ample runway. High price‑to‑sales (~9.8) embeds significant pipeline execution expectations.

Technically, MRNA shows a strong bullish inflection. This week’s move from a 46.5–49.7 consolidation to a breakout close near 56.3, on elevated volume, confirms a trend reversal from prior mid‑$40s resistance now turned support. Intraday 5‑minute action shows persistent dip‑buying above 54 with shallow pullbacks, suggesting strong institutional demand. Actionable level: 54 is the key pivot; long entries above 54 with a stop near 50 and first target at 60 align with the new uptrend.

Near term, sentiment is improving as Q1 beats, EU approval of the flu/COVID combo mCOMBRIAX, and visible late‑stage oncology and rare‑disease assets reposition Moderna among large‑cap biotech peers. While profitability lags sector medians, its balance sheet and pipeline depth compare favorably to Biotechnology & Life Sciences benchmarks. With multiple 2026 clinical and regulatory catalysts, I see a justified re‑rating. Fair trading range is $50–65 over 12 months, with support at $50–54 and resistance near $60–65.

Quick Financial Overview

Moderna Inc. delivered Q1 2026 revenue of $389M, more than tripling year over year and sharply above the roughly $236M Street view. The catch is the headline $1.3B GAAP net loss, which was largely driven by a $0.9B non-recurring litigation settlement rather than a collapse in the core business. For short-term MRNA traders, that split matters: operating momentum is improving while reported earnings still look ugly.

Margins remain deeply negative, with EBIT margin around -141% and profit margin near -144%, showing that Moderna Inc. is still in an aggressive build-out and transition phase. At the same time, a 55.7% gross margin and a price-to-sales ratio near 9.8 tell you the market is paying up for future optionality, not current profits. The balance sheet helps support that story: cash, equivalents, and short-term investments total roughly $5.2B, current ratio is about 3.3, and debt levels are modest with total debt-to-equity near 0.15.

Cash flow is the other side of the coin. Operating cash flow was -$630M in the quarter, and free cash flow ran about -$692M, underscoring ongoing burn as Moderna Inc. funds its pipeline. Management still guides to 2026 year-end cash of $4.5–$5.0B after R&D near $3B and SG&A around $1B, which gives MRNA a multi-year runway if execution stays on track. That runway is what supports continued Street interest even with no dividend and negative current earnings.

More Breaking News

On the tape, MRNA shows active momentum. The weekly data for early May 2026 capture a sharp move: after trading in the high $40s, the stock spiked to the mid-$50s, with a close around $56.32 after an intraday range that stretched from under $49 to nearly $58. That wide 5-minute candle range on the earnings reaction day reflects aggressive buying interest and profit-taking, classic post-earnings volatility.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading MRNA

Millionaire's
POV on MRNA

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”